# PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

> **NCT03006432** · PHASE3 · COMPLETED · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 507 (actual)

## Conditions studied

- OESOPHAGO-GASTRIC CARCINOMA

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** 5Fluorouracil bolus
- **DRUG:** 5Fluorouracil continu
- **DRUG:** Docetaxel
- **DRUG:** Folinic Acid

## Key facts

- **NCT ID:** NCT03006432
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-19
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2025-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006432, "PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03006432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*